John Lee
2022 - Decibel Therapeutics
In 2022, John Lee earned a total compensation of $733.2K as Executive Vice President, Chief Development Officer at Decibel Therapeutics, a 10% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $134,100 |
---|---|
Option Awards | $137,004 |
Salary | $447,015 |
Other | $15,038 |
Total | $733,157 |
Lee received $447K in salary, accounting for 61% of the total pay in 2022.
Lee also received $134.1K in non-equity incentive plan, $137K in option awards and $15K in other compensation.
Rankings
In 2022, John Lee's compensation ranked 3,664th out of 5,683 executives tracked by ExecPay. In other words, Lee earned more than 35.5% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 3,664 | 36th |
Manufacturing | 2,081 | 33rd |
Chemicals And Allied Products | 1,003 | 29th |
Drugs | 940 | 28th |
Pharmaceutical Preparations | 684 | 28th |
Lee's colleagues
We found three more compensation records of executives who worked with John Lee at Decibel Therapeutics in 2022.
News
Marathon Patent Group CFO Hugh Gallagher receives $4.8M in 2022
June 23, 2023
Decibel Therapeutics CEO Laurence Reid's 2022 pay jumps 54% to $1.2M
April 28, 2023
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2021 pay slips 13% to $1.5M
April 22, 2022
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2019 pay jumps 102% to $1.2M
April 24, 2020
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2018 pay jumps 37% to $596K
April 5, 2019